Hundreds of Scottish businesses set to benefit as UK Government invests in new roles to boost exporting –

UK health secretary steps in to offer long-term waiting list support in Wales and Scotland –

UK annual defence procurement worth more than £2 billion to Scotland – Gov.UK

First monoclonal antibody treatment for COVID-19 approved for use in the UK –

Click the image below to read more:

Following on from a thorough review of the evidence carried out by the MHRA, and recommendation by the Commission on Human Medicines (CHM), the government’s independent expert scientific advisory body, the MHRA has approved Ronapreve as the first monoclonal antibody combination product indicated for use in the prevention and treatment of acute COVID-19 infection for the UK.

Developed by Regeneron/Roche, the drug is administered either by injection or infusion and acts at the lining of the respiratory system where it binds tightly to the coronavirus and prevents it from gaining access to the cells of the respiratory system. Clinical trial data assessed by a dedicated team of MHRA scientists and clinicians has shown that Ronapreve may be used to prevent infection, promote resolution of symptoms of acute COVID-19 infection and can reduce the likelihood of being admitted to hospital due to COVID-19.